NS-2359

NS-2359 (also known as GSK-372,475) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that was under development by GlaxoSmithKline (GSK) for clinical use as an antidepressant, but was discontinued in 2009. It was being investigated for its potential to treat major depressive disorder and as a possible smoking cessation aid.

Pharmacology

NS-2359 is a potent inhibitor of the reuptake of serotonin, norepinephrine, and dopamine. This triple reuptake inhibition makes NS-2359 a unique antidepressant. The compound's activity at the three neurotransmitter transporters is believed to confer a superior therapeutic profile compared to traditional SSRIs and SNRIs.

Clinical Trials

Phase I and II clinical trials were conducted by GSK to assess the safety, tolerability, and efficacy of NS-2359. However, the development of the drug was discontinued in 2009. The reasons for the discontinuation have not been publicly disclosed.

Potential Uses

Despite the discontinuation of its development, NS-2359 has been the subject of independent research due to its unique pharmacological profile. It has been suggested as a potential treatment for a variety of conditions including major depression, generalized anxiety, and as a potential aid in smoking cessation.

See Also

• Serotonin-norepinephrine-dopamine reuptake inhibitor
• GlaxoSmithKline
• Antidepressant
• Major depressive disorder
• Smoking cessation

This article is a stub related to pharmacology. You can help WikiMD by expanding it!

• 

  NS-2359 Structure